Amesite Reports 63% Revenue Growth from NurseMagic鈩� Enterprise; Announces Launch of AI-Powered Government Form-Fill Automation to Reduce Reporting Burden
Amesite (NASDAQ: AMST), an AI-powered enterprise solutions developer, reported 63% revenue growth for its NurseMagic鈩� platform following the July 14, 2025 launch of its census-based Enterprise subscription model. The company announced that Enterprise sales have surpassed B2C sales, driven by post-acute care providers seeking scalable compliance solutions.
Amesite also launched an AI-powered automated form fill solution for government forms, specifically targeting the upcoming Centers for Medicare & Medicaid Services (CMS) mandate for Hospice Outcomes and Patient Evaluation (HOPE) assessment. The solution aims to help healthcare organizations auto-populate complex forms, reduce administrative time, and ensure full reimbursements in a market growing at a CAGR of 8%.
Amesite (NASDAQ: AMST), sviluppatore di soluzioni aziendali basate sull'IA, ha registrato una crescita dei ricavi del 63% per la sua piattaforma NurseMagic鈩� dopo il lancio, avvenuto il 14 luglio 2025, del modello di abbonamento Enterprise basato sulla censitura. L'azienda ha comunicato che le vendite Enterprise hanno superato quelle B2C, spinte da fornitori di assistenza post-acuta alla ricerca di soluzioni di conformit脿 scalabili.
Amesite ha inoltre introdotto una soluzione automatizzata di compilazione moduli potenziata dall'IA per i moduli governativi, con focus sul prossimo mandato dei Centers for Medicare & Medicaid Services (CMS) relativo alla valutazione Hospice Outcomes and Patient Evaluation (HOPE). La soluzione 猫 pensata per aiutare le organizzazioni sanitarie a precompilare moduli complessi, ridurre i tempi amministrativi e garantire rimborsi completi in un mercato che cresce a un CAGR dell'8%.
Amesite (NASDAQ: AMST), desarrollador de soluciones empresariales impulsadas por IA, inform贸 un crecimiento de ingresos del 63% en su plataforma NurseMagic鈩� tras el lanzamiento, el 14 de julio de 2025, de su modelo de suscripci贸n Enterprise basado en el censo. La compa帽铆a anunci贸 que las ventas Enterprise han superado a las B2C, impulsadas por proveedores de atenci贸n post-aguda que buscan soluciones de cumplimiento escalables.
Amesite tambi茅n lanz贸 una soluci贸n de llenado autom谩tico de formularios impulsada por IA para formularios gubernamentales, dirigida espec铆ficamente al pr贸ximo mandato de los Centers for Medicare & Medicaid Services (CMS) sobre la evaluaci贸n Hospice Outcomes and Patient Evaluation (HOPE). La soluci贸n pretende ayudar a las organizaciones sanitarias a autocompletar formularios complejos, reducir el tiempo administrativo y asegurar reembolsos completos en un mercado que crece a un CAGR del 8%.
Amesite (NASDAQ: AMST)電� AI 旮半皹 鞐旐劙頂勲澕鞚挫 靻旊（靺� 臧滊皽鞐呾泊搿�, 2025雲� 7鞗� 14鞚� 鞚戈惮 旮办(靹检劀鞀�) Enterprise 甑弲 氇嵏 於滌嫓 鞚错泟 鞛愳偓 NurseMagic鈩� 頂岆灚韽检潣 毵れ稖鞚� 63% 歃濌皜
Amesite電� 霕愴暅 鞝曤秬 鞏戩嫕鞖╈溂搿� 靹り硠霅� AI 旮半皹 鞛愲彊 鞏戩嫕 鞛戩劚 靻旊（靺�鞚� 於滌嫓頄堨溂氅�, 韸鬼瀳 CMS(Centers for Medicare & Medicaid Services)鞚� 靸堧鞖� Hospice Outcomes and Patient Evaluation(HOPE) 韽夑皜 鞚橂頇旍棎 雽�鞚戫晿電� 瓴冹潉 氇╉憸搿� 頃╇媹雼�. 鞚� 靻旊（靺橃潃 鞚橂 旮瓣磤鞚� 氤奠灐頃� 鞏戩嫕鞚� 鞛愲彊鞙茧 毂勳毎瓿� 頄夓爼 鞁滉皠鞚� 欷勳澊氅� 鞕勳爠頃� 頇橁笁鞚� 氤挫灔頃橂弰搿� 霃曤弰搿� 靹り硠霅橃棃鞙茧┌, 甏�霠� 鞁滌灔鞚� 鞐绊弶攴� 靹膘灔毳�(CAGR) 8%搿� 靹膘灔頃橁碃 鞛堨姷雼堧嫟.
Amesite (NASDAQ: AMST), d茅veloppeur de solutions d'entreprise aliment茅es par l'IA, a annonc茅 une croissance des revenus de 63% pour sa plateforme NurseMagic鈩� suite au lancement, le 14 juillet 2025, de son mod猫le d'abonnement Enterprise bas茅 sur le recensement. L'entreprise a indiqu茅 que les ventes Enterprise ont d茅pass茅 les ventes B2C, tir茅es par des prestataires de soins post-aigus recherchant des solutions de conformit茅 茅volutives.
Amesite a 茅galement lanc茅 une solution automatis茅e de remplissage de formulaires aliment茅e par l'IA pour les formulaires gouvernementaux, ciblant sp茅cifiquement le prochain mandat des Centers for Medicare & Medicaid Services (CMS) concernant l'茅valuation Hospice Outcomes and Patient Evaluation (HOPE). La solution vise 脿 aider les organisations de sant茅 脿 pr茅remplir automatiquement des formulaires complexes, 脿 r茅duire le temps administratif et 脿 garantir des remboursements complets sur un march茅 en croissance 脿 un Taux de croissance annuel compos茅 (CAGR) de 8%.
Amesite (NASDAQ: AMST), ein Entwickler KI-gest眉tzter Unternehmensl枚sungen, meldete nach dem Start seines census-basierten Enterprise-Abonnementmodells am 14. Juli 2025 ein Umsatzwachstum von 63% f眉r die Plattform NurseMagic鈩�. Das Unternehmen gab bekannt, dass Enterprise-Verk盲ufe die B2C-Verk盲ufe 眉bertroffen haben, getrieben von post-akuten Pflegeanbietern, die skalierbare Compliance-L枚sungen suchen.
Amesite hat au脽erdem eine KI-gest眉tzte automatisierte Formularausf眉lll枚sung f眉r Regierungsformulare eingef眉hrt, die speziell auf das bevorstehende Mandat der Centers for Medicare & Medicaid Services (CMS) zur Hospice Outcomes and Patient Evaluation (HOPE) abzielt. Die L枚sung soll Gesundheitsorganisationen helfen, komplexe Formulare automatisch vorzubef眉llen, Verwaltungszeiten zu reduzieren und vollst盲ndige Erstattungen sicherzustellen 鈥� in einem Markt mit einem CAGR von 8%.
- Revenue growth of 63% for NurseMagic platform
- Enterprise sales surpassing B2C sales, indicating successful business model transition
- Launch of AI-powered HOPE automation solution addressing upcoming regulatory requirements
- Operating in post-acute care market with 8% CAGR growth rate
- None.
Insights
Amesite's 63% revenue growth from NurseMagic Enterprise and new AI form automation position it well in expanding post-acute care market.
Amesite's 63% revenue growth for its NurseMagic platform signals strong market validation for its AI-powered enterprise approach in the post-acute care sector. The shift from B2C to Enterprise sales represents a strategic pivot with significantly higher revenue potential per customer. Rather than selling to individual healthcare workers, Amesite now targets entire organizations with census-based pricing that scales with patient populations.
The timing of their new AI-powered government form automation is particularly strategic ahead of CMS's mandatory HOPE assessment implementation in October. This regulatory change will substantially increase documentation requirements for hospice providers already facing staffing shortages. By automating these complex documentation processes, Amesite addresses a critical pain point that directly impacts reimbursement rates for providers.
What's most significant is Amesite's differentiated approach from traditional EMR vendors. While legacy systems often add documentation burden, Amesite's AI automation promises to reduce administrative time while maintaining compliance - essentially allowing providers to handle more patients without proportionally increasing staff. This positions them advantageously in the post-acute care market, which is growing at an 8% CAGR, outpacing acute care.
The company's focus on ensuring full reimbursement rates through compliant documentation directly addresses a top financial concern for healthcare providers. With increasing regulatory scrutiny, solutions that can simultaneously reduce administrative burden while improving compliance represent substantial value in this specialized market segment.
DETROIT, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading developer of AI-powered enterprise solutions, today announced
"We鈥檙e no longer just selling to employees 鈥� we鈥檙e selling to serve every patient in the system and help organizations leverage AI technology as a true competitive advantage," said Brandon Owens, VP of Sales at Amesite. "That changes the game. The total addressable market is exponentially larger, and our pricing reflects the performance of our solution. Customers are choosing NurseMagic鈩� Enterprise to scale operations without adding staff, addressing one of the greatest costs in healthcare."
The announcement comes as the Centers for Medicare & Medicaid Services (CMS) prepares to mandate the Hospice Outcomes and Patient Evaluation (HOPE) assessment this October 鈥� a regulatory overhaul expected to significantly increase documentation burden per patient and strain already thin hospice staffing cohort. Amesite鈥檚 AI-powered HOPE automation solution, within NurseMagic鈩� Enterprise, is designed to enable organizations to auto-populate complex forms, cut administrative time, and assure full reimbursements.
"The government鈥檚 scrutiny of documentation is intensifying, and many organizations are unprepared," said Kalie Wortinger, Senior Engineering Manager at Amesite. "With the HOPE requirement looming, providers are seeking a solution that enables compliant, reimbursable submission of documentation. NurseMagic鈩� Enterprise has modular intelligence that enables our customers to document compliantly, and to be fully reimbursed for the crucial work they do."
"We鈥檝e taken an entirely different approach from traditional EMR vendors," said Dr. Ann Marie Sastry, CEO of Amesite. "Our platform reimagines how post-acute care organizations handle regulatory requirements, enabling them to leverage our AI-powered tools to scale operations without adding staff. We specifically designed our solution to be an essential edge for customers, in a highly competitive, and demographically inevitable, market."
The post-acute care market is growing faster than the acute care market at a .
Post-acute care owners can book a demo to learn more about NurseMagic鈩⑩�檚 HOPE solution .
About Amesite Inc.
Amesite (NASDAQ: AMST) is an AI-driven company with an immediate aim to transform the
Forward-Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company's planned online machine learning platform, the Company's business plans, any future commercialization of the Company's online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company's filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations
FAQ
What was Amesite's (NASDAQ: AMST) revenue growth for NurseMagic in 2025?
What is Amesite's new AI-powered solution for healthcare providers?
How is Amesite addressing the upcoming CMS HOPE mandate?
What is the growth rate of the post-acute care market where Amesite operates?
How has Amesite's business model evolved with NurseMagic?
